ET-1 Lys198Asn and ETA receptor H323H polymorphisms in heart failure -: A case-control study

被引:26
作者
Colombo, Maria Giovanna
Ciofini, Enrica
Paradossi, Umberto
Bevilacqua, Stefano
Biagini, Andrea
机构
[1] CNR, Inst Clin Physiol, Massa, Italy
[2] Univ Pisa, Scuola Super Sant Anna, Pisa, Italy
关键词
enclothelin-1; endothelin receptors; heart failure;
D O I
10.1159/000092374
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The endothelin (ET) system plays a central role in the control of myocardial function and its pathophysiology. The aim of the present study was to explore whether genetic variations of ET-1 (G/T substitution that predicts an Lys/Asn change at codon 198) and its receptor ETA (T/C in exon 6, H323H) could predispose carriers to heart failure (HF). Methods: Genotyping at these two loci was done in 122 patients with HF [echocardiographic left ventricular ejection fraction (LVEF)<= 40%] and 216 age-matched subjects without HF. Causes of HF included ischemic (n = 96) and idiopathic cardiomyopathies (n = 26). Results: The ET-1 Lys198Asn was significantly associated with the occurrence of HF (p = 0.005). The risk of HF was independently increased among Asn/Asn in comparison to Lys carriers (OR = 3.2, p = 0.03). Moreover, homozygous carriers of both ET-1 and ETA variants showed a marked increase in the risk of HF (adjusted OR = 8.6, p = 0.005), displayed significantly lower LVEF (p = 0.002) and higher left ventricular end-diastolic (p = 0.03) and end-systolic diameters (p = 0.04; for Asn/Asn and TT vs. Lys and C carriers of the ET-1 and ETA Polymorphisms, respectively). Furthermore, the extent of coronary artery disease (r = -0.62, p < 0.0001) and the Asn/Asn and TT double genotype (r = -0.30, p = 0.0001) were the only significant and independent predictors of LVEF by multivariate analysis. Conclusions: The ET-1 Lys198Asn and ETA receptor H323H polymorphisms seem to act synergistically to increase the risk of HF. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:246 / 252
页数:7
相关论文
共 31 条
[1]  
Adams Kirkwood F. Jr., 2001, American Journal of Medicine, V110, p6S
[2]   Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].
Anand, I ;
McMurray, J ;
Cohn, JN ;
Konstam, MA ;
Notter, T ;
Quitzau, K ;
Ruschitzka, F ;
Lüscher, TF .
LANCET, 2004, 364 (9431) :347-354
[3]   Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects - The Ohasama study [J].
Asai, T ;
Ohkubo, T ;
Katsuya, T ;
Higaki, J ;
Fu, YX ;
Fukuda, M ;
Hozawa, A ;
Matsubara, M ;
Kitaoka, H ;
Tsuji, I ;
Araki, T ;
Satoh, H ;
Hisamichi, S ;
Imai, Y ;
Ogihara, T .
HYPERTENSION, 2001, 38 (06) :1321-1324
[4]   Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy [J].
Barden, AE ;
Herbison, CE ;
Beilin, LJ ;
Michael, CA ;
Walters, BN ;
Van Bockxmeer, FM .
JOURNAL OF HYPERTENSION, 2001, 19 (10) :1775-1782
[5]   Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: The EVA study [J].
Funalot, B ;
Courbon, D ;
Brousseau, T ;
Poirier, O ;
Berr, C ;
Cambien, F ;
Amouyel, P ;
Schwartz, JC ;
Ducimetiere, P .
JOURNAL OF HYPERTENSION, 2004, 22 (04) :739-743
[6]   A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy [J].
Herrmann, SM ;
Schmidt-Petersen, K ;
Pfeifer, J ;
Perrot, A ;
Bit-Avragim, N ;
Eichhorn, C ;
Dietz, R ;
Kreutz, R ;
Paul, M ;
Osterziel, KJ .
EUROPEAN HEART JOURNAL, 2001, 22 (20) :1948-1953
[7]   Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro [J].
Iglarz, M ;
Benessiano, J ;
Philip, I ;
Vuillaumier-Barrot, S ;
Lasocki, S ;
Hvass, U ;
Durand, G ;
Desmonts, JM ;
Lévy, BI ;
Henrion, D .
HYPERTENSION, 2002, 39 (02) :209-213
[8]   Association of endothelin-1 gene variant with hypertension [J].
Jin, JJ ;
Nakura, J ;
Wu, ZH ;
Yamamoto, M ;
Abe, M ;
Tabara, Y ;
Yamamoto, Y ;
Igase, M ;
Kohara, K ;
Miki, T .
HYPERTENSION, 2003, 41 (01) :163-167
[9]   Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [J].
Kalra, PR ;
Moon, JCC ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (2-3) :195-197
[10]   Endothelin expression and the progression of heart failure - Exemplifying the vagaries of therapeutic development [J].
Konstam, MA ;
DeNofrio, D .
CIRCULATION, 2004, 109 (02) :143-145